In the KEYS trial, addition of which chemotherapy agent to adjuvant chemoradiation after radical hysterectomy for high-risk cervical cancer improved disease-free survival?

• A Pembrolizumab
• B Nivolumab
• C Paclitaxel
• D Bevacizumab ✓

Explanation

The KEYS trial evaluated addition of bevacizumab (anti-VEGF monoclonal antibody) to adjuvant chemoradiation in high-risk cervical cancer after radical surgery. Bevacizumab improved disease-free survival. In the GOG 240 trial, bevacizumab also improved overall survival in recurrent/metastatic cervical cancer when added to chemotherapy. Pembrolizumab is approved for recurrent PD-L1 positive cervical cancer.

Reference: Shaw's Textbook of Gynaecology, 17th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.